Glenmark is committed to bringing responsible pain management medication to patients experiencing pain by developing innovative, differentiated products. Our goal is to research and discover medicines that will contribute to improving health outcomes for individuals suffering from pain. Glenmark has two early stage pain candidates. GRC 27864 is a non-opioid, selective and orally bioavailable inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1), while GRC 17536 is a TRPA1 antagonist.

Click here to view our innovative pipeline.